Placeholder Banner

BIO Comments to FDA on the draft guidance “Regulatory Consideration for Prescription Drug Use-Related Software.”

December 18, 2023

In response to the request for information and comments, BIO submitted general comments and recommended edits on the draft guidance (FDA-2023-D-2482)

Download Full Comments Below
BIO Comment Letter - FDA-2023-D-2482 - Prescription Drug Use-Related Software
Discover More
“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the United States and the cornerstone of America’s…